Renal Business Today

Medical Directors Concerned About Bundle, Patient Outcomes

EXTON, Pa.—Medical directors report a significantly higher awareness of the dialysis bundle and have become decidedly more negative about the impact to patient outcomes, according to new results released March 24 by BioTrendsResearch Group. ...More

March 24, 2010

Posted in News, Business, Clinical & Pharma, Government & Regulation, Practice Management

Genzyme Launches 1 mcg Hectorol Capsules

CAMBRIDGE, Mass.—Genzyme Corp. announced Aug. 10 that it has launched a 1 mcg formulation of Hectorol (doxercalciferol capsules). ...More

August 11, 2009

Posted in News, Business, Clinical & Pharma

Genzyme Sues Sandoz over Hectorol Patent

WILMINGTON, Del.—Genzyme has sued the Sandoz Inc. unit of Novartis AG for allegedly infringing on its patent for Hectorol, according to a July 17 report from Bloomberg. ...More

July 21, 2009

Posted in News, Business, Clinical & Pharma

Report: Product Shifts in Renal Anemia, Bone, Mineral Metabolism Markets

EXTON, Pa.—Product shifts are occurring in the renal anemia and bone and mineral metabolism markets, according to BioTrends Research Group’s most recent TreatmentTrends®: US Nephrology Report syndicated report based on online survey results of more than 200 ...More

April 28, 2009

Posted in News, Business, Clinical & Pharma, Practice Management

Genzyme Launches Vial Formulation of Hectorol Injection

CAMBRIDGE, Mass.—Genzyme Corp. announced April 7 that it has launched a vial formulation of Hectorol (doxercalciferol injection). ...More

April 7, 2009

Posted in News, Business, Clinical & Pharma, Practice Management

Genzyme to Launch New Hectorol IV Vial, 1 mcg Capsule

CAMBRIDGE, Mass.—Genzyme will launch a vial formulation of Hectorol as well as a 1 mcg capsule of the secondary hyperparathyroidism drug, according to a company executive. ...More

January 22, 2009

Posted in News, Business, Clinical & Pharma

Nephrologists settling into new anemia treatment standards

EXTON, Pa.— Nephrologists appear to be settling into new renal anemia treatment standards, and more than two-thirds do not anticipate making any additional changes to their use of anemia drugs in chronic kidney disease or dialysis, according to a new report. ...More

October 28, 2008

Posted in News, Business, Clinical & Pharma, Practice Management

ESA use decreases in pre-dialysis patients, study says

EXTON, Pa.—Safety concerns regarding anemia drugs have led to a decrease in the use of erythropoiesis-stimulating agents in predialysis patients, according to a recent report. ...More

May 7, 2008

Posted in News, Business, Clinical & Pharma, Government & Regulation

Safety concerns affect anemia management

EXTON, Pa.--Approximately 80 percent of nephrologists said that safety concerns surrounding erythropoiesis-stimulating agents have affected their management of anemia, according to a new report released by BioTrends Research Group. The U.S. Food and Drug Administration ...More

January 29, 2008

Posted in News, Business, Clinical & Pharma, Government & Regulation

Computers & Software	Consulting, Management...
Equipment & Services	Hemodialysis Supplies
Patient Services	More Options...

Hectorol

Mobile Health Snaps

Galleries

Most Popular Articles

Buyer's Guide

Resources

Free Email Updates

featured links

First Name	Last Name
E-Mail